Celldex Therapeutics (NASDAQ:CLDX) Price Target Cut to $50.00 by Analysts at Barclays

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its price objective cut by equities researchers at Barclays from $53.00 to $50.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s target price would indicate a potential upside of 79.75% from the stock’s current price.

A number of other equities research analysts have also recently commented on CLDX. HC Wainwright reduced their target price on shares of Celldex Therapeutics from $64.00 to $58.00 and set a “buy” rating for the company in a report on Friday. Morgan Stanley boosted their price target on Celldex Therapeutics from $57.00 to $61.00 and gave the company an “overweight” rating in a research report on Monday, November 9th. Stifel Nicolaus set a $68.00 price objective on Celldex Therapeutics in a research note on Tuesday, September 22nd. Cantor Fitzgerald increased their price objective on Celldex Therapeutics from $61.00 to $72.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Thursday, October 15th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $63.33.

Check Out Our Latest Research Report on Celldex Therapeutics

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock opened at $27.82 on Friday. The firm’s fifty day simple moving average is $31.11 and its 200-day simple moving average is $32.83. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -6.40 and a beta of 1.04. Celldex Therapeutics has a 12 month low of $22.33 and a 12 month high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.06. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.72 million. Analysts anticipate that Celldex Therapeutics will post -4.12 earnings per share for the current year.

Hedge Funds Weigh In On Celldex Therapeutics

A number of large investors have recently bought and sold shares of the company. Three Bridge Wealth Advisors LLC purchased a new position in Celldex Therapeutics during the 3rd quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Celldex Therapeutics in the third quarter valued at about $42,000. Nykredit A S purchased a new stake in shares of Celldex Therapeutics in the second quarter valued at about $67,000. Sterling Capital Management LLC boosted its holdings in shares of Celldex Therapeutics by 355.2% in the third quarter. Sterling Capital Management LLC now owns 2,376 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 1,854 shares in the last quarter. Finally, State of Wyoming increased its stake in shares of Celldex Therapeutics by 347.3% during the third quarter. State of Wyoming now owns 2,943 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 2,285 shares during the period.

Celldex Therapeutics Company Profile

(Get Free Report)

Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells. The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity. Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.

See Also

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.